Navigation Links
Altrazeal(TM) Clinical Evidence to be Presented at The American Professional Wound Care Association (APWCA) National Clinical Conference 2009
Date:4/1/2009

ADDISON, Texas, April 1 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) announced today that clinical evidence on the treatment of wounds using Altrazeal(TM) Transforming Powder Dressing, and data on the physical properties of Altrazeal(TM) Silver will be presented at the annual APWCA National Clinical Conference in Philadelphia, April 2-5, 2009. The work will be presented in podium presentations and with posters on display during the meeting.

Renaat Van den Hooff, President and CEO of ULURU Inc., commented: "Since the launch of Altrazeal(TM) in June 2008, we have accumulated extensive clinical experience across all wound types. The presentation of this data in a formal forum is a reflection of the execution of an important part of our 2009 business strategy."

Dr. Brock Liden, DPM of the Berger Health Care Center in Circleville, Iowa, will discuss at one podium presentation a talk titled "Treatment methods and experience with a novel aggregating powder dressing." In this presentation, Dr. Liden will detail his experiences and best clinical practice using Altrazeal(TM), application techniques, and what to expect when applying and treating wounds with the dressing.

In addition, clinical evidence using Altrazeal(TM) in treatment of diabetic foot ulcers, surgical wounds, and difficult to treat wounds such as those on sickle cell patients or patients afflicted with lymphangioma or pyoderma will be presented. A total of five posters detailing clinical evidence of Altrazeal(TM) will be displayed including one that shows the successful use of Altrazeal(TM) under contact casts in the treatment of diabetic foot ulcers. Commenting on the product, Dr. Greg Bohn, MD, FACS, Medical Director of the Trinity Center for Wound Care and Hyperbaric Medicine in Bettendorf, Iowa, and author of three of the posters stated, "Altrazeal(TM) is proving to be a very versatile dressing in wound care. The ability to apply it for up to 30 days and combine it with other substances will have substantial impact in the wound care field."

Dr. John St. John, the Company's Vice President of Research and Development, will present a podium presentation on the development path of Altrazeal(TM) and the Altrazeal(TM) family of wound dressings.

In addition, another poster will be presented with data on the biocompatibility and physical properties of Altrazeal(TM) Silver. The Company will also exhibit Altrazeal(TM) Transforming Powder Dressing at a booth during APWCA, demonstrating the mechanism of action and ease of application for wound care professionals in attendance.

Details of APWCA are available online at http://www.apwca.org/apwca2009.

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative transmucosal delivery system and Nanoflex(TM) Aggregate technology. For further information about ULURU Inc., please visit our website at www.uluruinc.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the benefits, effectiveness, biocompatibility, ease of application, success in wound healing, and suitability of Altrazeal(TM) and the success of our clinical efforts. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Renaat Van den Hooff
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145


'/>"/>
SOURCE ULURU Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ULURU Inc. Announces the Launch of the Altrazeal(TM) Website
2. ULURU Inc. Hosts Symposium on Altrazeal(TM) at the 23rd Annual Clinical Symposium on Advances in Skin & Wound Care
3. ULURU Inc. Announces the Launch Plan for Altrazeal(TM)
4. Upcoming Symposium to Bridge the Gap between Osteoporosis Research and its Applications to Clinical Practice with Focus on Secondary Osteoporosis, Osteoporosis in Men, and Lessons from Space Travel for Improving Bone Health
5. By shutting down inflammation, agent reverses damage from spinal cord injury in preclinical studies
6. Australian clinical trials threatened: Jobs and patient access to new treatments at stake
7. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
8. Pathwork Tissue of Origin Test Validation Study Published in Journal of Clinical Oncology
9. Task Force Recommends Screening Adolescents for Clinical Depression
10. Hard to Treat Diseases (HTDS) clinical trial protocol for MMR Vaccine expected Q2 2009
11. Catastrophic Head and Neck Injuries Among Focus for NFL Team Physicians and Clinical Staff at Fourth Annual Injuries in Football Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to expand ... Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final WNBA ... levels of the game, Connor Sports has committed to a significantly increased focus on ...
(Date:5/26/2016)... ... ... MadgeTech will be showcasing its line of data logging products , ... MadgeTech headquarters. With products sold in more than 100 countries around the world, MadgeTech ... , In 2012, NASA strategically set up 17 RHTemp101A MadgeTech data loggers around ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... May 27, 2016 Amarantus BioScience Holdings, ... developing products for Regenerative Medicine, Neurology and Orphan Diseases, today announced ... presenting at two upcoming investor conferences: SeeThru Equity ... Avenue, New York City , NY ... Marcum MicroCap Conference   Where: Grand Hyatt Hotel, ...
(Date:5/26/2016)... , May 26, 2016 ... With Both Cost Savings and Overall Decreased ... (LSE: BTG), an international specialist healthcare company, has ... the 21st Annual Meeting of ISPOR (International Society ... of hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres ...
(Date:5/25/2016)... -- According to a new market research ... by Therapeutic Area (Oncology, Cosmeceutical/Plastic Surgery), by Application (Drug ... Hospitals/ Clinics) - Forecast to 2021", published by MarketsandMarkets, ... the forecast period of 2016 to 2021. This market ... from USD 117.3 Million in 2016, at a CAGR ...
Breaking Medicine Technology: